Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Cerus: Firm receives five-year $50 mil. loan commitment from Baxter Capital. Funds become available in January 2003, and no interest or principle is due until 2008. Proceeds will be used to commercialize the Intercept blood filter system (1"The Gray Sheet" Sept. 30, 2002, p. 22). Baxter and Cerus have been collaborating on blood filtration systems since 1993. "Baxter's willingness to provide this funding underscores their confidence in the success of the Intercept," CEO Stephen Isaacs comments an Oct. 31 release announcing the transaction...